Research

We seek to combine biology and engineering to develop new human therapies. One particularly important problem is the quest to deliver drugs, inside of specific cell targets, in vivo. There are many macromolecular drugs, such as DNA, RNA and some proteins, with great therapeutic potential that will only function when inside of a cell. We have developed synthetic nanoparticles that can act like artificial viruses, delivering genetic therapies in vivo to selectively turn genes off, turn them on, or even permanently edit the genome. We are also working to develop new biomaterials and approaches to tissue engineering. By developing smart biomaterials that can interact appropriately with the immune system, we have made living medical devices, that can secrete drugs on demand as needed by the body for chronic disease such as diabetes. Finally, we continue to focus our efforts towards developing next generation nanotherapeutics for cancer, by developing vaccines and methods to control immune cell function. These advances have led products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer products space.

Super biocompatible materials for islet transplantation

Super biocompatible materials for islet transplantation

Glucose responsive drug delivery systems and sensors

Glucose responsive drug delivery systems and sensors

Genome editing

Genome editing

Delivery of nucleic acid based therapies

Delivery of nucleic acid based therapies

Biomaterials for the growth, controlled differentiation, and therapeutic use of stem cells

Biomaterials for the growth, controlled differentiation, and therapeutic use of stem cells